$CATX
Perspective Therapeutics Inc Stock $catx

$catx Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-K Financial Statement

#000114420417050344 Filed on September 28, 2017

Income Statement

Concept	2017 Q3	2016 Q2	2016 Q1
Revenue	$1.211M	$1.120M	$1.198M
YoY Change	12.03%	-16.46%	3.44%
Cost Of Revenue	$946.0K	$1.170M	$1.132M
YoY Change	-8.42%	2.63%	2.64%
Gross Profit	$265.0K	-$48.00K	$66.00K
YoY Change	452.08%	-123.42%	19.57%
Gross Profit Margin	21.88%	-4.29%	5.51%
Selling, General & Admin	$1.455M	$1.520M	$1.211M
YoY Change	0.28%	32.17%	25.52%
% of Gross Profit	549.06%		1834.85%
Research & Development	$362.0K	$140.0K	$183.0K
YoY Change	110.47%	-12.5%	29.42%
% of Gross Profit	136.6%		277.27%
Depreciation & Amortization	$18.00K	$140.0K	$140.0K
YoY Change	12.5%	-6.67%	0.0%
% of Gross Profit	6.79%		212.12%
Operating Expenses	$1.817M	$1.200M	$1.394M
YoY Change	11.95%	-7.69%	26.02%
Operating Profit	-$1.552M	-$1.248M	-$1.327M
YoY Change	-1.46%	13.97%	26.26%
Interest Expense	$10.00K	$70.00K	$0.00
YoY Change	-83.33%	0.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net	$6.000K	-$460.0K	$132.0K
YoY Change	-92.21%		35.44%
Pretax Income	-$1.550M	-$1.180M	-$1.200M
YoY Change	3.33%	14.56%	26.32%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$1.546M	-$1.185M	-$1.195M
YoY Change	3.2%	14.53%	25.32%
Net Earnings / Revenue	-127.66%	-105.8%	-99.75%
Basic Earnings Per Share
Diluted Earnings Per Share	-$28.17K	-$21.44K	-$21.81K
COMMON SHARES
Basic Shares Outstanding	55.02M shares	55.01M shares	55.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2016 Q2	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.260M	$12.39M	$11.61M
YoY Change	-47.05%	-15.08%	14.27%
Cash & Equivalents	$3.956M	$10.14M	$5.694M
Short-Term Investments	$3.300M	$2.250M	$5.910M
Other Short-Term Assets	$410.0K	$27.00K	$290.0K
YoY Change	57.69%	1.15%	31.82%
Inventory	$453.0K	$334.0K	$457.3K
Prepaid Expenses
Receivables	$740.0K	$600.0K	$880.0K
Other Receivables	$0.00	$108.00	$5.098K
Total Short-Term Assets	$8.866M	$13.63M	$13.24M
YoY Change	-40.62%	-16.52%	11.36%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.090M	$577.0K	$415.7K
YoY Change	55.71%	0.38%	-37.02%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$2.970M	$5.190M
YoY Change		-41.88%	-48.87%
Other Assets	$217.0K	$151.0K	$222.5K
YoY Change	-71.82%	-38.38%	-65.76%
Total Long-Term Assets	$1.915M	$4.473M	$6.556M
YoY Change	8.81%	-33.02%	-43.92%
TOTAL ASSETS
Total Short-Term Assets	$8.866M	$13.63M	$13.24M
Total Long-Term Assets	$1.915M	$4.473M	$6.556M
Total Assets	$10.78M	$18.10M	$19.80M
YoY Change	-35.4%	-21.31%	-16.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$810.0K	$610.0K	$730.0K
YoY Change	65.31%	22.0%	65.91%
Accrued Expenses	$260.0K	$480.0K	$480.0K
YoY Change	-58.73%	-18.64%	9.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.067M	$1.094M	$1.212M
YoY Change	-4.73%	0.17%	37.76%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$570.0K	$610.0K	$1.060M
YoY Change	-3.39%	-46.02%	-4.5%
Total Long-Term Liabilities	$570.0K	$610.0K	$1.060M
YoY Change	-3.39%	-46.02%	-4.5%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.067M	$1.094M	$1.212M
Total Long-Term Liabilities	$570.0K	$610.0K	$1.060M
Total Liabilities	$1.635M	$1.701M	$2.271M
YoY Change	-4.39%	-23.41%	14.25%
SHAREHOLDERS EQUITY
Retained Earnings	-$74.15M	-$66.44M	-$65.26M
YoY Change	9.14%	7.63%	7.51%
Common Stock	$83.30M	$82.84M	$82.78M
YoY Change	0.46%	0.39%	150731.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Treasury Stock Shares		0.000 shares	0.000 shares
Shareholders Equity	$9.146M	$16.40M	$17.52M
YoY Change
Total Liabilities & Shareholders Equity	$10.78M	$18.10M	$19.80M
YoY Change	-35.39%	-21.31%	-16.06%

Cashflow Statement

Concept	2017 Q3	2016 Q2	2016 Q1
OPERATING ACTIVITIES
Net Income	-$1.546M	-$1.185M	-$1.195M
YoY Change	3.2%	14.53%	25.32%
Depreciation, Depletion And Amortization	$18.00K	$140.0K	$140.0K
YoY Change	12.5%	-6.67%	0.0%
Cash From Operating Activities	-$1.661M	-$1.200M	-$760.0K
YoY Change	22.76%	90.48%	-32.74%
INVESTING ACTIVITIES
Capital Expenditures	$54.00K	-$230.0K	-$210.0K
YoY Change	-63.27%	283.33%	425.0%
Acquisitions
YoY Change
Other Investing Activities	-$260.0K	$5.880M	$5.980M
YoY Change	766.67%	23.79%	550.0%
Cash From Investing Activities	-$315.0K	$5.660M	$5.760M
YoY Change	-3.67%	20.43%	562.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		0.000	0.000
YoY Change		-100.0%
NET CHANGE
Cash From Operating Activities	-1.661M	-1.200M	-760.0K
Cash From Investing Activities	-315.0K	5.660M	5.760M
Cash From Financing Activities		0.000	0.000
Net Change In Cash	-1.976M	4.460M	5.000M
YoY Change	17.62%	7.73%	-2023.08%
FREE CASH FLOW
Cash From Operating Activities	-$1.661M	-$1.200M	-$760.0K
Capital Expenditures	$54.00K	-$230.0K	-$210.0K
Free Cash Flow	-$1.715M	-$970.0K	-$550.0K
YoY Change	14.33%	70.18%	-49.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	605000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	323000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	271000	USD
CY2016Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	304000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	10291000	USD
CY2016Q2	us-gaap	Assets Current AssetsCurrent	13629000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1054000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	577000	USD
CY2017Q2	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2016Q4	dei	Entity Public Float EntityPublicFloat	31910103	USD
CY2017	dei	Trading Symbol TradingSymbol	ISR
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55017419	shares
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5932000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10139000	USD
CY2017Q2	us-gaap	Short Term Investments ShortTermInvestments	3039000	USD
CY2016Q2	us-gaap	Short Term Investments ShortTermInvestments	2247000	USD
CY2017Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	726000	USD
CY2016Q2	us-gaap	Inventory Net InventoryNet	334000	USD
CY2016Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	580000	USD
CY2016Q2	us-gaap	Long Term Investments LongTermInvestments	2973000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000	USD
CY2016Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	181000	USD
CY2017Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	513000	USD
CY2016Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	591000	USD
CY2017Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	125000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	55000	USD
CY2016Q2	us-gaap	Common Stock Value CommonStockValue	55000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	83151000	USD
CY2016Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	82788000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-72604000	USD
CY2016Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-66442000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	10602000	USD
CY2016Q2	us-gaap	Stockholders Equity StockholdersEquity	16401000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12269000	USD
CY2016Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	18102000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	1667000	USD
CY2017Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	630000	USD
CY2016Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	612000	USD
CY2017Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	75000	USD
CY2016Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	177000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	138000	USD
CY2016Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	72000	USD
CY2017Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	138000	USD
CY2016Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	111000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1106000	USD
CY2016Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1094000	USD
CY2017Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	0	USD
CY2016Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	27000	USD
CY2017Q2	us-gaap	Asset Retirement Obligations Noncurrent AssetRetirementObligationsNoncurrent	561000	USD
CY2016Q2	us-gaap	Liabilities Liabilities	1701000	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4761000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4769000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3923000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4640000	USD
CY2017	us-gaap	Gross Profit GrossProfit	838000	USD
CY2016	us-gaap	Gross Profit GrossProfit	129000	USD
CY2017	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2310000	USD
CY2016	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1353000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3918000	USD
CY2016	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3786000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	7145000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	5211000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-6307000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-5082000	USD
CY2017	us-gaap	Investment Income Interest InvestmentIncomeInterest	118000	USD
CY2016	us-gaap	Investment Income Interest InvestmentIncomeInterest	218000	USD
CY2017	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	27000	USD
CY2016	us-gaap	Unrealized Gain Loss On Derivatives UnrealizedGainLossOnDerivatives	154000	USD
CY2017	us-gaap	Interest Expense InterestExpense	0	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-4337000	USD
CY2016	us-gaap	Interest Expense InterestExpense	1000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	145000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	371000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-6162000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-4711000	USD
CY2017	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000	USD
CY2016	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000	USD
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6173000	USD
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4722000	USD
CY2017	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
CY2016	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2017	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55016000	shares
CY2016	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55015000	shares
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	4606000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4439000	USD
CY2015	us-gaap	Gross Profit GrossProfit	167000	USD
CY2015	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1488000	USD
CY2015	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2401000	USD
CY2015	us-gaap	Investment Income Interest InvestmentIncomeInterest	283000	USD
CY2015	us-gaap	Interest Expense InterestExpense	2000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	656000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	-3681000	USD
CY2015	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	11000	USD
CY2015	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3692000	USD
CY2015	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.07
CY2015	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	54882000	shares
CY2015	us-gaap	Operating Expenses OperatingExpenses	4504000	USD
CY2017	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	48000	USD
CY2016	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	456000	USD
CY2015	us-gaap	Asset Retirement Obligation Revision Of Estimate AssetRetirementObligationRevisionOfEstimate	0	USD
CY2017	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	372000	USD
CY2017	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11000	USD
CY2017	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	4000	USD
CY2016	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	0	USD
CY2017	us-gaap	Depreciation And Amortization DepreciationAndAmortization	68000	USD
CY2016	us-gaap	Depreciation And Amortization DepreciationAndAmortization	471000	USD
CY2017	us-gaap	Adjustment For Amortization AdjustmentForAmortization	45000	USD
CY2016	us-gaap	Adjustment For Amortization AdjustmentForAmortization	107000	USD
CY2017	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	29000	USD
CY2016	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	89000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	372000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	290000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	184000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-444000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-89000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	23000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-100000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	21000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	18000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	112000	USD
CY2017	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-47000	USD
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000	USD
CY2017Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2016	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	50000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-9000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	39000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4207000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	4912000	USD
CY2016	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	-2000	USD
CY2017	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-52000	USD
CY2016	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	48000	USD
CY2017	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	66000	USD
CY2016	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-141000	USD
CY2017	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	27000	USD
CY2016	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	-16000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5712000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3884000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13000	USD
CY2016	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	15492000	USD
CY2017	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	115000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	1514000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	8757000	USD
CY2017	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2016	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2015Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	5227000	USD
CY2017	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	0	USD
CY2016	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	0	USD
CY2017	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000	USD
CY2017	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	USD
CY2016	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000	USD
CY2017	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2016	us-gaap	Inventory Write Down InventoryWriteDown	72000	USD
CY2015	isr	Provision For Reduction Of Doubtful Accounts ProvisionForReductionOfDoubtfulAccounts	9000	USD
CY2015	us-gaap	Depreciation And Amortization DepreciationAndAmortization	576000	USD
CY2015	us-gaap	Adjustment For Amortization AdjustmentForAmortization	37000	USD
CY2015	us-gaap	Asset Retirement Obligation Accretion Expense AssetRetirementObligationAccretionExpense	81000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	205000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	127000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	144000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	24000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-77000	USD
CY2015	us-gaap	Increase Decrease In Other Accrued Liabilities IncreaseDecreaseInOtherAccruedLiabilities	44000	USD
CY2015	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-12000	USD
CY2015	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-23000	USD
CY2015	us-gaap	Increase Decrease In Other Employee Related Liabilities IncreaseDecreaseInOtherEmployeeRelatedLiabilities	7000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3522000	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	18000	USD
CY2015	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	15873000	USD
CY2015	us-gaap	Payments To Acquire Longterm Investments PaymentsToAcquireLongtermInvestments	14938000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	784000	USD
CY2015	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	82000	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	214000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	285000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2453000	USD
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7680000	USD
CY2015	isr	Supplemental Common Stock Warrant Liability Reclassification SupplementalCommonStockWarrantLiabilityReclassification	17000	USD
CY2015	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	11000	USD
CY2015	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2015	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2017	us-gaap	Interest Paid InterestPaid	0	USD
CY2016	us-gaap	Interest Paid InterestPaid	1000	USD
CY2015	us-gaap	Interest Paid InterestPaid	2000	USD
CY2017	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	323000	USD
CY2015	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	151000	USD
CY2016	us-gaap	Marketing And Advertising Expense MarketingAndAdvertisingExpense	157000	USD
CY2016Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	12000	USD
CY2017Q2	us-gaap	Prepaid Advertising PrepaidAdvertising	11000	USD
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3438256	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3214211	shares
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2863147	shares
CY2017Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	191000	USD
CY2016Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	155000	USD
CY2017Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	121000	USD
CY2016Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	161000	USD
CY2017Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	11000	USD
CY2016Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	18000	USD
CY2017Q2	us-gaap	Prepaid Insurance PrepaidInsurance	52000	USD
CY2016Q2	us-gaap	Prepaid Insurance PrepaidInsurance	46000	USD
CY2017Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	122000	USD
CY2016Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	231000	USD
CY2017Q2	us-gaap	Other Assets Current OtherAssetsCurrent	30000	USD
CY2016Q2	us-gaap	Other Assets Current OtherAssetsCurrent	27000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7591000	USD
CY2016Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7541000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	285000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	519000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	610000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8645000	USD
CY2016Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	8118000	USD
CY2017	isr	Asset Retirement Obligation Period Increase Decrease In Estimate Gain Loss AssetRetirementObligationPeriodIncreaseDecreaseInEstimateGainLoss	48000	USD
CY2016	isr	Asset Retirement Obligation Period Increase Decrease In Estimate Gain Loss AssetRetirementObligationPeriodIncreaseDecreaseInEstimateGainLoss	456000	USD
CY2017Q2	us-gaap	Asset Retirement Obligation AssetRetirementObligation	561000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	2150000	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	1185500	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	395000	shares
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	372000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	290000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	205000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	3000	USD
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	25000	USD
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	307000	USD
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	664000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	545000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	9000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Loss Reserves DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLossReserves	13000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	33000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Other DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther	119000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	196000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Asset Retirement Obligations DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAssetRetirementObligations	203000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	21302000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19110000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	22723000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	20600000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22723000	USD
CY2016Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	20600000	USD
CY2017Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2016Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-2157000	USD
CY2016	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1649000	USD
CY2015	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1288000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	17000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	7000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	10000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	16000	USD
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	21000	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	19000	USD
CY2017	isr	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-9000	USD
CY2016	isr	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-54000	USD
CY2015	isr	Income Tax Reconciliation Change In Fair Value Of Warrants IncomeTaxReconciliationChangeInFairValueOfWarrants	-131000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2123000	USD
CY2016	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1675000	USD
CY2015	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1390000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-1195000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	285000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	285000	USD
CY2017	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	288000	USD
CY2016	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	292000	USD
CY2015	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	280000	USD
CY2017Q2	isr	Number Of Employees Commitment NumberOfEmployeesCommitment	25	pure
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1081000	USD
CY2016Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1028000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1282000	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1370000	USD
CY2016Q3	us-gaap	Gross Profit GrossProfit	48000	USD
CY2016Q4	us-gaap	Gross Profit GrossProfit	-1000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	293000	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	498000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-1498000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-1450000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-1360000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-1854000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2016Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2015Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1261000	USD
CY2015Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1189000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1198000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1120000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	83000	USD
CY2015Q4	us-gaap	Gross Profit GrossProfit	30000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	66000	USD
CY2016Q2	us-gaap	Gross Profit GrossProfit	-48000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-1019000	USD
CY2015Q4	us-gaap	Net Income Loss NetIncomeLoss	-1312000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-1185000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2015Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2016Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55013000	shares
CY2015Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55014000	shares
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55023000	shares
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55012000	shares
CY2016	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	6000	USD
CY2015	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	12000	USD
CY2016	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	6000	USD
CY2015	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	12000	USD
CY2016	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	0	USD
CY2015	us-gaap	Cost Of Property Repairs And Maintenance CostOfPropertyRepairsAndMaintenance	0	USD
CY2016Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	0	USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	26000	USD
CY2016Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	30000	USD
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017	isr	Federal Deposit Insurance Corporation Limits On Deposits In Financial Institutions FederalDepositInsuranceCorporationLimitsOnDepositsInFinancialInstitutions	250000	USD
CY2016Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	7001671	shares
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2016Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	192998329	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55017419	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55017419	shares
CY2016Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55010619	shares
CY2016Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55010619	shares
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN-TOP: 0pt; FONT: 10pt Times New Roman, Times, Serif; MARGIN-BOTTOM: 0pt" align="center"></div> <table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT: 10pt Times New Roman, Times, Serif" cellspacing="0" cellpadding="0"> <tr style="VERTICAL-ALIGN: top"> <td style="WIDTH: 0.25in"> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> 1.</b></font></div> </td> <td> <div><font style="FONT-FAMILY:Times New Roman, Times, Serif"><b> Organization</b></font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">IsoRay, Inc. was incorporated in Minnesota in 1983. On July 28, 2005, IsoRay Medical, Inc. (Medical) became a wholly-owned subsidiary of IsoRay, Inc. (formerly known as Century Park Pictures Corporation) pursuant to a merger. Medical was formed under Delaware law on June 15, 2004 and on October 1, 2004 acquired two affiliated predecessor companies which began operations in 1998. Medical, a Delaware corporation, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. Medical is headquartered in Richland, Washington.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">IsoRay International LLC (International), a Washington limited liability company, was formed on November 27, 2007 and is a wholly-owned subsidiary of IsoRay, Inc. International has entered into various international distribution agreements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	237000	USD
CY2017Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1092000	USD
CY2017Q2	us-gaap	Area Of Land AreaOfLand	4.2	acre
CY2017	isr	Purchase Obligation Expiration Date PurchaseObligationExpirationDate	2017-03-31
CY2017	isr	Purchase Obligation Agreement Period PurchaseObligationAgreementPeriod	P1Y
CY2017	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	771000	USD
CY2016Q4	us-gaap	Purchase Obligation PurchaseObligation	854000	USD
CY2017Q2	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	504000	USD
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"><u>Use of Estimates</u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">The preparation of consolidated financial statements in accordance with generally accepted accounting principles in the United States of America requires management of the Company to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes of the Company including the allowance for doubtful accounts receivable; net realizable value of the enriched barium inventory; the estimated useful lives used in calculating depreciation and amortization on the Company’s fixed assets, patents, trademarks and other assets; estimated amount and fair value of the asset retirement obligation related to the Company’s production facilities; and inputs to the Black-Scholes calculation used in determining the expense related to share-based compensation including volatility, estimated lives and forfeiture rates of options granted. Accordingly, actual results could differ from those estimates and affect the amounts reported in the financial statements.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2016	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	528000	USD
CY2015	isr	Research And Development Proprietary Research And Development ResearchAndDevelopmentProprietaryResearchAndDevelopment	615000	USD
CY2017	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	194000	USD
CY2016	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	0	USD
CY2015	isr	Research And Development Collaboration Services Net Of Reimbursement ResearchAndDevelopmentCollaborationServicesNetOfReimbursement	0	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	965000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	528000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	615000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	47000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	34000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	24000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	23000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	23000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	79000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	230000	USD
CY2015Q4	us-gaap	Purchase Obligation PurchaseObligation	1000000	USD
CY2017Q2	us-gaap	Land Land	365900	USD
CY2017Q2	us-gaap	Payments To Acquire Land Held For Use PaymentsToAcquireLandHeldForUse	168000	USD
CY2017Q2	us-gaap	Payments To Acquire Land Held For Use PaymentsToAcquireLandHeldForUse	197900	USD
CY2017	isr	Asset Retirement Obligation Assumed Creditadjusted Risk Free Rate AssetRetirementObligationAssumedCreditadjustedRiskFreeRate	0.051	pure
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	133000	USD
CY2017	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	6000	USD
CY2016	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2015	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2017Q2	isr	Estimated Asset Retirement Cost EstimatedAssetRetirementCost	650000	USD
CY2017	isr	Asset Retirement Obligation Assumed Inflation Factor AssetRetirementObligationAssumedInflationFactor	0.011	pure
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	23956000	USD
CY2015	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	100000	USD
CY2015	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	213000	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	20782000	USD
CY2015	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	205000	USD
CY2016	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	50000	USD
CY2016	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	0	USD
CY2016	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	11000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	291000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	549000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	479000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0183	pure
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y9M18D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y11M23D
CY2014Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	444747	shares
CY2015	isr	Issuanceofcommonstockinconnectionwithwarrantexercisesnetofissuancecostsshares Issuanceofcommonstockinconnectionwithwarrantexercisesnetofissuancecostsshares	58947	shares
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	385800	shares
CY2016	isr	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	155713	shares
CY2016Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	230087	shares
CY2017	isr	Class Of Warrant Or Right Expired In Period ClassOfWarrantOrRightExpiredInPeriod	230087	shares
CY2017Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	0	shares
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.43
CY2015	isr	Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights	1.38
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.22
CY2016	isr	Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights	1.63
CY2016Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.94
CY2017	isr	Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights Classofwarrantorrightexpiredinperiodweightedaverageexercisepriceofwarrantsorrights	0.94
CY2017Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1.47
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0162	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0051	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0162	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0142	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0165	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.01	pure
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.03	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.06	pure
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.18	pure
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.07	pure
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3187000	USD
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M8D
CY2015	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y8M16D
CY2016	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y11M5D
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M10D
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	3.48
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.67
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.89
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.21
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.61
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	2.55
CY2017	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.26
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.78
CY2017	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y6M
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2418282	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1185500	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2150000	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	459594	shares
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	509904	shares
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	162869	shares
CY2016	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	56260	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	111000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	148000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	151000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1800441	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3274591	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.93
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	0.78
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.91
CY2016	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.87
CY2017	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	6800	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2925059	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3379191	shares
CY2016Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	263000	USD
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	692000	USD
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2314422	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	395000	shares
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	84236	shares
CY2015	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	206904	shares
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.00
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.41
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.15
CY2015	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	1.03
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	857000	USD
CY2017Q2	isr	Percentage Of Royalty Rate Payable PercentageOfRoyaltyRatePayable	0.01	pure
CY2017Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	67000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	912000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1008000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	45000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	107000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37000	USD
CY2017	isr	Increase Decrease In Estimate On Patents And Trademarks IncreaseDecreaseInEstimateOnPatentsAndTrademarks	0	USD
CY2016	isr	Increase Decrease In Estimate On Patents And Trademarks IncreaseDecreaseInEstimateOnPatentsAndTrademarks	73000	USD
CY2015	isr	Increase Decrease In Estimate On Patents And Trademarks IncreaseDecreaseInEstimateOnPatentsAndTrademarks	0	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	151000	USD
CY2017	us-gaap	Payments To Acquire Land Held For Use PaymentsToAcquireLandHeldForUse	168000	USD
CY2017Q2	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	195000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	10000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	230000	USD
CY2016Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	151000	USD
CY2017Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	778000	USD
CY2016Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	761000	USD
CY2017Q2	isr	Share Based Compensation Costs For Recognized ShareBasedCompensationCostsForRecognized	51000	USD
CY2017	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
CY2016	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	8000	USD
CY2015	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55011000	shares
CY2016Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55017000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55017000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55017000	shares
CY2017	isr	Share Based Compensation Arrangement By Share Based Payment Award Options Voided In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVoidedInPeriodWeightedAverageExercisePrice	0.94
CY2017	isr	Share Based Compensation Arrangement By Share Based Payment Award Options Voided ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVoided	-1179164	shares
CY2016	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	USD
CY2015	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	0	USD
CY2016	isr	Asset Retirement Obligation Assumed Inflation Factor AssetRetirementObligationAssumedInflationFactor	0.011	pure
CY2016	isr	Asset Retirement Obligation Assumed Creditadjusted Risk Free Rate AssetRetirementObligationAssumedCreditadjustedRiskFreeRate	0.051	pure
CY2016Q2	isr	Estimated Asset Retirement Cost EstimatedAssetRetirementCost	650000	USD
CY2017Q2	isr	Share Based Compensation Costs For Replacement Options ShareBasedCompensationCostsForReplacementOptions	494000	USD
CY2017Q1	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	3537500	USD
CY2017Q2	isr	Total Amount Of Purchase Obligation TotalAmountOfPurchaseObligation	1862000	USD

Files In Submission

Name	View Source	Status
0001144204-17-050344-index-headers.html	Edgar Link	pending
0001144204-17-050344-index.html	Edgar Link	pending
0001144204-17-050344.txt	Edgar Link	pending
0001144204-17-050344-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
isr-20170630.xml	Edgar Link	completed
isr-20170630.xsd	Edgar Link	pending
isr-20170630_cal.xml	Edgar Link	unprocessable
isr-20170630_def.xml	Edgar Link	unprocessable
isr-20170630_lab.xml	Edgar Link	unprocessable
isr-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v475122_10k.htm	Edgar Link	pending
v475122_ex21-1.htm	Edgar Link	pending
v475122_ex23-1.htm	Edgar Link	pending
v475122_ex31-1.htm	Edgar Link	pending
v475122_ex31-2.htm	Edgar Link	pending
v475122_ex32.htm	Edgar Link	pending
v475122_img1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CATX
Perspective Therapeutics Inc Stock $catx

2017 Q3 Form 10-K Financial Statement

#000114420417050344 Filed on September 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX Perspective Therapeutics Inc Stock $catx

2017 Q3 Form 10-K Financial Statement

#000114420417050344 Filed on September 28, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CATX
Perspective Therapeutics Inc Stock $catx